EMAIL THIS PAGE TO A FRIEND

Journal of pharmaceutical sciences

Phospholipid vesicle-based permeation assay and EpiSkin® in assessment of drug therapies destined for skin administration.


PMID 25558045

Abstract

Cost-effective and efficient methods for permeability screening are crucial during early development of drugs, drug formulations, and cosmeceuticals. Alternatives to animal experiments are impelled for both economical and ethical reasons. The aim of this study was to determine the ability of the phospholipid vesicle-based permeation assay (PVPA) to assess the effect of different formulations on drug permeability and thus establish its utility in formulation development. Three model drugs were tested in solutions and as liposomal formulations. The permeability results for the PVPA models were compared with the results for the reconstructed human skin model, EpiSkin(®). The drugs were ranked based on their estimated penetration potentials, and the results were in accordance with what was expected considering the physicochemical properties of the drugs. PVPAs (E-80, ceramide, cholesterol, cholesteryl sulfate, and palmitic acid) was able to distinguish between drug solutions and liposomal formulations; however, EpiSkin(®) detected only small differences between the drugs in solution and formulations. In contrast with EpiSkin(®), which is limited by a 3-day testing window, PVPA barriers can be stored frozen for up to 2 weeks or even up to 16 months, depending on their compositions. The PVPA models are thus more cost effective and efficient than the EpiSkin(®) model for permeability screening during early drug development.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

81780
1,3-Propanediol, puriss., ≥99.0% (GC)
C3H8O2
P50404
1,3-Propanediol, 98%
C3H8O2
A0220000
Aciclovir, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
Y0001271
Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
Y0001269
Aciclovir for peak identification 2, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
Y0001264
Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
A4669
Acycloguanosine, ≥99% (HPLC), powder
C8H11N5O3
1012065
Acyclovir, United States Pharmacopeia (USP) Reference Standard
C8H11N5O3
PHR1254
Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material
C8H11N5O3
P5585
Palmitic acid, BioXtra, ≥99%
C16H32O2
P0500
Palmitic acid, ≥99%
C16H32O2
P0625
Palmitic acid, Grade II, ~95%
C16H32O2
43051
Palmitic acid, certified reference material, TraceCERT®
C16H32O2
1492007
Palmitic acid, United States Pharmacopeia (USP) Reference Standard
C16H32O2
76119
Palmitic acid, analytical standard
C16H32O2
27734
Palmitic acid, ≥98% palmitic acid basis (GC)
C16H32O2
76122
Palmitic acid, purum, ≥98.0% (GC)
C16H32O2
W283207
Palmitic acid, ≥95%, FCC, FG
C16H32O2
PHR1120
Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material
C16H32O2
P0090000
Palmitic acid, European Pharmacopoeia (EP) Reference Standard
C16H32O2
W283215
Palmitic acid, natural, 98%, FG
C16H32O2